^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review
Published date:
08/28/2023
Excerpt:
This study reports the case of a 57-year-old male diagnosed as having stage IIIC squamous cell lung cancer. Oncomine Dx Target Test identified EGFR exon19 deletion and de novo EGFR T790M mutation with variant allele frequencies (VAF) of 21.6% and 25.2%, respectively. The patient was treated with osimertinib after progression on chemoradiotherapy followed by durvalumab, and a partial response was maintained for more than 20 months.
DOI:
https://doi.org/10.1111/1759-7714.15081
Source:
Title:
Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: A case report and literatures review
Excerpt:
A case of a 66-year-old man with advanced SCC who was deemed inoperable at the time of diagnosis. The first genetic testing showed deletion mutation of exon 19 of EGFR….EGFR-T790M mutation was found in the second genetic test. The treatment regimen was changed to radiotherapy with Osimertinib and the patient's primary lesion and the brain metastases were well controlled.
DOI:
10.3389/fonc.2023.1188772
